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Background: SLCO1B1 polymorphisms are relevant in statin pharmacokinetics. Aim of this study was to investigate
the genetic variability and haplotype profile of SLCO1B1 polymorphisms in Roma and Hungarian populations.
Genotypes of 470 Roma and 442 Hungarian subjects for c.388A > G, c.521T > C and c.1498-1331T > C
polymorphisms were determined by PCR-RFLP assay. Using these SNPs eight different haplotypes could be
differentiated.
Results: Differences were found between Roma and Hungarians in SLCO1B1 388AA (24.5 vs. 45.5 %), GG (33.4 vs.
17.9 %) genotypes, AG + GG (75.5 vs. 54.5 %) carriers, in G allele frequency (0.545 vs. 0.362), respectively (p < 0.001).
The most common SLCO1B1 haplotype was the ht8 (GTT) both in Roma (43.6 %) and in Hungarian (59.1 %)
samples. The ht6 (GCT) was not present in Roma population samples Haplotype analyses showed striking
differences between the Roma and Hungarian samples in ht4 (ATT, 37.2 % vs 20.8 %), ht5 (GCC, 1.15 % vs. 3.62 %)
and ht8 (GTT, 43.6 % vs. 59.1 %) haplotypes (p < 0.01), respectively. Linkage disequilibrium analysis showed that the
studied variants are in different linkage disequilibrium patterns depending on the ethnic origin.
Conclusions: Similarly to Caucasians the 388G is the minor allele in Hungarians, however, in Roma the 388A was
found to be the minor allele contrary to Indians (India). The minor allele frequency of 521T > C and 1498-1331T > C
SNPs are almost three times higher in Romas than in Indians (Singapore and Gujarati, respectively). Observed allele
frequency for 1498-1331T > C polymorphism reflects the measured average European rates in Hungarians. The results
can be applied in population specific treatment algorithms when developing effective programs for statin therapy.
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Solute carrier organic anion transporter family member
1B1 (SLCO1B1) (alternative names OATP2, OATPC,
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article, unless otherwise stated.endogenous substrates (e.g. bile acids), xenobiotics and a
wide panel of pharmaceutical compounds (e.g. statins,
antibiotics, ACE inhibitors). OATP1B1 protein mediates
active intracellular hepatic transport of anionic com-
pounds, important in drug hepatic clearance and in
general drug disposition [1]. General role of the uptake
transporter is removal of substrates from the blood into
the liver. Sequence variations play an important role in
pharmaceutical response to a number of drugs [2].
SLCO1B1 gene is located on chromosome 12 (15 exons,
190 common variants) and encodes a 691 amino acid pro-
tein with 12 transmembrane helices [3, 4]. OATP1B1 isis distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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hepatocytes, where it mediates active intracellular hepatic
transport of various anionic compounds [5, 6].
OATP1B1-dependent transport is an important step in
mediating drug hepatic clearance. Statins (HMG-CoA
reductase inhibitors) are widely prescribed for cardiovas-
cular disease (CVD) risk reduction [1, 7]. OATP1B1 trans-
port is particularly important for hepatic accessibility of
pravastatin, as this compound is too hydrophilic to gain
significant hepatocellular entry through passive transport
[8]. OATP1B1-dependent transport could well be import-
ant for the acid (active) form of simvastatin, (and other
statins less hydrophobic than pravastatin) as SLCO1B1
variants were recently associated with simvastatin-induced
myopathies [9], implying that OATP1B1 was involved
with simvastatin transport. The SLCO1B1 gene spans
fifteen exons and 190 common variants with minor allele
frequency greater than 5 % (http://hapmap.ncbi.nlm.nih.
gov/). Of these, two common non-synonymous SLCO1B1
variants have been well characterized: rs2306283 (388A >G,
N130D) and rs4149056 (T521C, V174A) [10]. Recent
reviews describe the role of OATP1B1 in general drug
disposition [4] and, specifically, in statin pharmacokinetics
[7]. Another recent discovery found the C variant of the
rs4363657 polymorphism of SLCO1B1 gene strongly asso-
ciated with statin induced myopathy in more than 60 % of
cases [11]. The association with myopathy was underlined
by several other studies with simvastatin and atorvastatin
[9, 12]. However, there appears to be no increased risk of
myalgia among users of rosuvastatin who carry the
rs4363657C allele in SLCO1B1 [13].
Several studies indicate the wide substrate selectivity of
OATP1B1 and demonstrate that sequence variation at the
SLCO1B1 locus may have a sizable impact on pharma-
ceutical. Consequently, importance of SLCO1B1 genetic
variants in clinical pharmacogenetics is underlined by the
fact that there are some drugs (e.g. simvastatin) on the
basis of the US Food and Drug Administration recom-
mendations have already incorporated information regard-
ing pharmacogenetic information about the SLCO1B1 in
their drug label (www.fda.gov). Extensive literature and
FDA warning labels indicate increased risk for myopathy
in patients with specific genetic differences on the
SLCO1B1 gene. Guidelines regarding the use of pharma-
cogenomic tests in dosing for simvastatin have been pub-
lished in Clinical Pharmacology and Therapeutics by the
Clinical Pharmacogenetics Implementation Consortium
(CPIC) [14].
Regarding the high clinical importance of SLCO1B1
pharmacogene in drug dosing of statins, it is noteworthy
to evaluate the SLCO1B1 genotype not only of single pa-
tients, but also the general frequency of the polymor-
phisms in the whole populations of different ethnic
background. Beside the main population of Hungariansthe Roma (Gypsy/Romani) minority forms the largest eth-
nic group in Hungary with specific genetic background
[15, 16]. Previous genetic studies revealed specific neuro-
muscular and other Mendelian disorders of the Roma
people caused by private founder mutations [17, 18]. The
unique and colorful population of Romani people is dis-
persed throughout the world. They are permanently mi-
grating, however they live predominantly in Central and
Eastern Europe. The major nation of Hungarians is genet-
ically heterogeneous. This may reflect the ancient origin
from the Eastern-Urals, important migratory routes
throughout the history and the recent admixture with
neighboring populations [19].
Accordingly, the genetic composition of Roma and
Hungarian populations differ from the European
Caucasians. Previous studies of several pharmacogenetically
relevant genes already revealed differences in genetic struc-
ture of Roma and Hungarian populations [20–22]. Until
now there is no report on the prevalence of the common
SLCO1B1 allelic variants in the constantly growing and
world-wide spread populations of Roma people. The ob-
jective of this study was to determine the frequencies and
haplotypes of SLCO1B1 variant alleles in Roma and
Hungarian populations, to compare our data to other
populations, mainly to Indians and Caucasians studied.
Population based screening can be used for risk stratifica-
tion in prevention programs at a population level.
Results and Discussion
The allele and genotype frequencies of the SLCO1B1
A388G, T521C and T89595C polymorphisms in Roma
and Hungarian populations are shown in Tables 1 and 2.
The allele and genotype frequency distribution was in ac-
cordance with Hardy-Weinberg equilibrium in Roma and
Hungarian subjects. The results of genotyping by PCR-
RFLP were in concordance with direct sequencing of
randomly selected wild type, heterozygous and homozy-
gous variant samples.
Significant differences were found comparing the Roma
and Hungarian populations in the SLCO1B1 388 AA (24.5
vs. 45.5 %), GG (33.4 vs. 17.9 %) genotypes, AG +GG
(75.5 vs. 54.5 %) carriers and in G allele frequency (0.545
vs. 0.362) (p < 0.001), respectively. Furthermore, the
frequency of SLCO1B1 521 TT (67.0 vs. 65.2 %) was
significantly higher in Roma than in Hungarian population
samples (p = 0.05). No significant difference was observed
in SLCO1B1T521C and the rs4363657 genotypes and
minor allele frequencies between the Roma and
Hungarian population samples.
The major haplotypes (ht) created by the examined
SLCO1B1 variants are shown in Table 3. The SLCO1B1
haplotype frequencies of Roma and Hungarians are sum-
marized in Table 4. The most common SLCO1B1 haplo-
type was the ht8 (GTT) both in Roma (43.6 %) and in
Table 1 Genotype and allele frequencies of SLCO1B1 exonic polymorphisms in healthy Roma and Hungarian population samples
compared to populations of different ethnic origin
Population Number G388A T521C Ref.
Percent Percent
AA1 AG GG1 AG + GG1 G allele1 TT2 TC CC TC + CC C allele
Roma 470 24.5 42.1 33.4 75.5 54.5 67.0 31.5 1.49 33.0 17.2 Current study
Hungarian 442 45.5 36.6 17.9 54.5 36.2 65.2 31.9 2.94 34.8 18.9 Current study
Finnish 468 29.3 49.2 21.6 70.8 46.2 63.9 31.8 4.30 36.1 20.2 [26]
Indian (North) 270 31.9 46.7 21.4 68.1 45.0 - - - - - [27]
Indian (Singapore) 100 17.0 52.0 31.0 83.0 57.0 87.0 13.0 0.00 13.0 6.50 [28]
Chinese (Singapore) 100 5.00 31.0 64.0 95.0 79.5 75.0 24.0 1.00 25.0 13.0 [28]
Chinese (Han) 111 9.00 35.1 55.9 91.0 73.4 73.8 24.3 1.80 26.1 14.0 [29]
Malays (Singapore) 100 2.00 22.0 76.0 98.0 87.0 79.0 20.0 1.00 21.0 11.0 [28]
Brazilian 143 55.9 35.7 8.40 44.1 26.2 74.1 23.8 2.10 25.9 14.0 [30]
Roma population is compared with Hungarians: 1p < 0.001 and 2p = 0.05
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present in Roma population samples. Haplotype ana-
lyses showed striking differences between the Roma
and Hungarian samples in ht4 (ATT, 37.2 % vs 20.8 %),
ht5 (GCC, 1.15 % vs. 3.62 %) and ht8 (GTT, 43.6 % vs.
59.1 %) haplotypes (p < 0.01), respectively.
Linkage disequilibrium analysis of SLCO1B1 rs2306283,
rs4149056 and rs4363657 variant alleles showed that the
studied alleles are in different linkage disequilibrium pat-
terns according to the different ethnic origin of Roma and
Hungarian populations (Fig. 1). The rs4149056 and
rs4363657 polymorphisms were in nearly complete link-
age disequilibrium both in Roma (LD = 95) and HungarianTable 2 Genotype and allele frequencies of SLCO1B1 intronic (T895




Roma 470 308 (65.5) 150 (31
Hungarian 442 285 (64.5) 141 (31
European (CEU) 113 77 (68.1) 35 (31
Italian 102 60 (58.8) 38 (37
Indian (Gujarati from Houston) 101 88 (87.1) 13 (12
Japanese (Tokyo) 113 44 (38.9) 49 (43
Chinese (Han) 135 44 (32.6) 60 (44
Chinese (Colorado) 108 34 (31.5) 44 (40
African (USA) 57 36 (63.2) 18 (31
Kenya (Luhya) 109 78 (71.6) 29 (26
Kenya (Maasai) 156 106 (67.9) 43 (27
Nigeria (Yoruban) 147 109 (74.1) 36 (24
Mexican (LA) 57 46 (80.7) 10 (17
No statistical difference was explored when Roma population was compared to Hu(LD = 96) populations. In addition, the Roma group pre-
sented also high degree of linkage disequilibrium in
SLCO1B1 rs2306283and rs4149056 SNPs (LD = 86).
Statins are used as prophylactic treatment to reduce
the risk of cardiovascular events. Statins have high inter-
individual pharmacokinetic variability, up to 10 fold or
more [23, 24].
The allele and genotype frequencies of SLCO1B1 gene
variants are dependent on ethnicity. Up to 2–5 % of in-
dividuals in various populations may be expected to
show markedly elevated plasma pravastatin concentra-
tions due to the SLCO1B1 polymorphisms [1]. There are
several disease conditions which have been found to be95C) polymorphism in healthy Roma and Hungarian population
Ref
CC TC + CC C allele
.9) 12 (2.60) 162 (34.5) 0.185 Current study
.9) 16 (3.60) 157 (35.5) 0.196 Current study
.0) 1 (0.90) 36 (31.9) 0.164 HapMap project
.3) 4 (3.90) 42 (41.2) 0.225
.9) 0 (0.00) 13 (12.9) 0.064
.4) 20 (17.7) 69 (61.1) 0.394
.4) 31 (23.0) 91 (67.4) 0.452
.7) 30 (27.8) 74 (68.5) 0.481
.6) 3 (5.30) 21 (36.9) 0.211
.6) 2 (1.80) 31 (28.4) 0.151
.6) 7 (4.50) 50 (32.1) 0.183
.5) 2 (1.40) 38 (25.9) 0.136
.5) 1 (1.80) 11 (19.3) 0.105
ngarians
Fig. 1 Linkage disequilibrium analysis for the SLCO1B1 rs2306283 (1),
rs4149056 (2) and rs4363657 (3) polymorphisms in Roma (a) and
Hungarian (b) populations
Table 3 Major haplotypes (ht) created by the examined
SLCO1B1 variants
rs2306283 rs4149056 r4363657
ht1 A C C
ht2 A C T
ht3 A T C
ht4 A T T
ht5 G C C
ht6 G C T
ht7 G T C
ht8 G T T
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The prevalence of SLCO1B1 genotypes and allele fre-
quencies reported from different ethnic populations res-
iding in different geographic areas are summarized in
Tables 1 and 2.
Similarly to other Caucasian populations the SLCO1B1
388G allele (rs2306283) is the minor allele in Hungarians,
however in Roma is the 388A was found to be the
minor allele, like in Indians from Singapore, however,
not in indigenous Indians from North of Indian sub-
continent (Table 1). The individuals that were homozy-
gous for the G allele of rs2306283 and glucose 6-
phosphate-dehydrogenase deficient were more frequent
among the neonatal hyperbilirubinemia cases [25].
The allele and genotype frequencies of SLCO1B1
rs4363657 noncoding polymorphism in Roma and
Hungarian populations compared with data from the
HapMap project are shown in Table 2. The observed
89595C allele frequency in Hungarians is slightly elevated
compared to Roma and average European population
(CEU) (http://hapmap.ncbi.nlm.nih.gov/). Interestingly, the
89595C allele frequency measured in Roma samples is al-
most three-fold higher than in Indians (Gujarati) and nearly
similar to data was found in Africans. When comparing to
other non-HapMap data, the C allele frequency of
rs4363657 SNP in Hungarian (19.6 %) and Roma (18.5 %)Table 4 Haplotype frequencies of the examined
SLCO1B1variants in Roma and Hungarian population samples









aRoma population is compared with Hungarians: p < 0.01populations found in our study was similar to that reported
for Caucasian subjects, 15.4 % [26] and 13.0 % (GWAS
study) [9]. Carrying the 89595C intronic variant means
markedly elevated exposure to simvastatin and increased
risk to myopathy [12, 27]. The odds ratio of SLCO1B1
rs4363657 for myopathy was 4.5 (95 % confidence interval
2.6-7.7) per copy of the C allele, and 16.9 (95 % confidence
interval 4.7-61.1) in CC as compared with TT homozygotes.
Genomic typing may allow the identification of these vari-
ants, leading to a tailored statin therapy with higher benefits
to the patients and less adverse side effects [27].
Interestingly, regarding SLCO1B1 rs2306283 SNP, Melo
et al. found significant differences in allele frequencies
when compared European Portugal population with the
data of HapMap CEU population [28]. Furthermore, in a
recent study investigated European Czech patients were
treated with low statin doses there was no association
Nagy et al. BMC Genetics  (2015) 16:108 Page 5 of 7found between rs4363657 SNP in SLCO1B1 and risk of
myalgia/myopathy [29].
The SLCO1B1 T521C SNP (rs4149056) is common in
non-African populations: Caucasian 8–20 %, Chinese
16 %, Japanese 10–16 % (Table 1). The minor allele
frequency of T521C SNP is almost three times higher in
Roma than in Indians (Singapore). Furthermore, the Roma
population differs also from Hungarians and Caucasians
in prevalence of this polymorphism. The results of
SLCO1B1 polymorphisms found in the Hungarian popula-
tion were similar to that observed in other Caucasian
populations. The 521C variant representing SLCO1B1
haplotype (*15) is associated with rifampin-induced liver
injury [30]. This non-synonymous coding SNP in SLCO1B1
markedly increases systemic exposure to simvastatin and
the risk of muscle toxicity. The strength of the evidence is
high for myopathy with simvastatin [14].
The most common SLCO1B1 haplotype was ht8 both in
Roma and Hungarian populations. In both examined pop-
ulations apart from ht8, the most frequent haplotype was
ht4 (containing neither variant) followed by ht1 (including
521C and 89595C intronic variants). The ht6 was present
in Hungarians with a low frequency (0.18), but was not
detectable in Roma samples. Ht2, representing the T521C
variant, is associated with decreased transporter activity
that may potentially be associated with increased statin
efficacy.
Conclusions
If we consider, these results suggest that the pharmaco-
genetical pattern of SLCO1B1 gene shows population
specificity; therefore the examination of clinically relevant
polymorphisms is important in different populations. The
phenotype effect of the SLCO1B1 haplotypes on the trans-
porter activity need to be investigated in future clinical
studies of these populations, as well as the effect on statin
treatment. Comparing the LD patterns of the two studied
populations we can conclude, Roma samples showed
higher degree of linkage disequilibrium of studied SNPs
than Hungarians. As both of the studied populations
present high degree of LD patterns, haplotypes analyses of
SLCO1B1 gene exerts less advantage, especially because




The DNA samples were from the central Biobank of the
University of Pecs that is part of the National Biobank
Network of Hungary, as well as the pan-European Biobank-
ing and Biomolecular Resources Research Infrastructure
(BBMRI) (http://bbmri-eric.eu/). The governance principles
and maintenance management of the Biobank had been
approved by the Hungarian National Research EthicsCommittee (ETT TUKEB, Budapest, Hungary). During
the collection and analysis of DNA samples and pro-
cessing of the accompanying personal data the guidelines
and regulations of the Helsinki Declaration in 1975 and the
currently operative National regulations were followed.
DNA of total of 470 healthy Roma samples (170 males and
300 females, mean age 39 ± 16 years, range: 18–93 years)
and 442 healthy Hungarian (183 males and 259 females,
mean age 45 ± 10 years, range: 18–66 years) were used in
the study. Informed consent was obtained from all subjects.
Molecular methods
Genomic DNA was isolated from peripheral leukocytes
using routine salting out method, and was store with the
patient’s informed consent. Three polymorphisms of the
SLCO1B1 (MIM*604843, 12p12) gene including the
rs2306283 (A388G, N130D, exon 5), the rs4149056
(T521C, V174A, exon 5) and rs4363657 (T89595C, intron
11) were analyzed. For primer design the sequences de-
posited into the GenBank (http://www.ncbi.nlm.nih.gov/
genbank/) were used.
Genotyping was carried out using polymerase chain
reaction (PCR) followed by restriction endonuclease diges-
tion (RFLP). For detection of the rs2306283 the following
primers were used: 5’-CTGTGTTGTTAATGGGCGAA-3’
and 5’-GGGGAAGATAATGGTGCAAA-3’. The rs4149
056 SNP was detected using the following set of
primers: 5'- TTGTCAAAGTTTGCAAAGTG -3’ forward
and 5’- GAAGCATATTACCCATGAGC -3’ reverse. And
the rs4363657 was detected with the help of the fol-
lowing primers: 5’-CAGTTTGCTAGTGTTTTGTTGAG
G-3’ forward, 5’-ACCATCCAAGACGAACAAAGAG -3’
reverse. Underlining in the sequence indicates mismatch
base introduced to generate artificial cleavage site. PCR
amplification was carried out in a final volume of 50 μl on
an MJ Research PTC 200 thermal cycler. PCR conditions
were as follows: predenaturation for 2 min at 96 °C,
followed by 30 cycles of denaturation for 30 s at 95 °C, an-
nealing for 1 min by primer specific temperature, primer
extension for 30 s at 72 °C, the final extension at 72 °C for
5 min. Annealing temperature for the A388G, T521C and
T89595C primers were 57, 52 and 55 °C, respectively.
Ten μl PCR products of the A388G, T521C and
T89595C primers was digested by Taq1, Hin6I and KpnI
restriction enzymes, respectively. Supplier of the restric-
tion endonucleases is the Thermo Scientific, the incuba-
tion temperature was 65, 37 and 37 °C, respectively. The
digested PCR products were separated by electrophoresis
using a 3 % agarose gel stained with ethidium bromide
and visualized by an UV transilluminator. In the ampli-
cons of the A388G polymorphism was an obligatory cleav-
age site to enable us to monitor the efficacy of the
digestion. In the samples with 388 AA genotype the Taq1
cleaves the 406-bp long PCR product in 159-bp and 247-
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gouse form the 23-, 136-, 247-bp fragments could be
detected. The 209-bp amplicon of the T521C SNP in the
samples with CC genotype was digested into 21-bp and
188-bp long fragments. While in TT homozygotes the
recognition site of the enzyme was missing, resulting in
no digestion. However, all the homozygote variant samples
from the PCR-RFLP assay were direct sequenced with the
same primers utilizing an ABI 3500 genetic analyzer.
Wild-type of 89595 TT yielded two fragments of 133 bp
and 236 bp in length, and the variant 89595 CC homozy-
gotes gave three fragments of 133 bp, 84 bp and 152 bp.
The heterozygotes formed four fragments of 84 bp,
133 bp, 152 bp and 236 bp. The accuracy of the genotyp-
ing was evaluated by direct sequence analysis of randomly
selected samples as described above.
Statistical analysis of data
The method used for calculation of the Hardy-Weinberg
equilibrium in different SNPs was described by G. H.
Hardy and W. Weinberg in 1908 [31].
Statistical significance (p < 0.05) was assessed by χ2 test
to compare the differences between studied groups. Stat-
istical analyses were performed applying Excel for Win-
dows and SPSS 11.5 package for Windows (SPSS Inc.,
Chicago, IL).
Haploview 4.1 was used to study linkage disequilibrium
(LD) patterns. We required the minor allele frequency at
each locus to be >0.05, with an R2 value of <0.8 between
pairs of loci, based on the default settings in Haploview.
Haplotype frequencies were estimated using PHASE ver-
sion 2.1 [32, 33]. The allele composition of major haplo-
types (ht) created by the examined SLCO1B1 variants is
shown in Table 3.Availability of supporting data
The identification numbers of the examined SNPs in
SLCO1B1 gene (Uniprot identifier: Q9Y6L6 is available at
http://www.uniprot.org/uniprot/Q9Y6L6) for c.521T >C,
c.388A >G and c.1498-1331T >C polymorphisms were
rs4149056, rs2306283 and rs4363657, respectively based on
the dbSNP database of NCBI (National Center for Biotech-
nology Information-http://www.ncbi.nlm.nih.gov/SNP/).
Abbreviations
SLCO1B1: Solute carrier organic anion transporter family member 1B1;
OATP1B1: Organic anion transporting polypeptide 1B1; PCR: Polymerase
chain reaction; RFLP: Restriction fragment length polymorphism; SNP: Single
nucleotide polymorphism; ht: Haplotype; LD: Linkage disequilibrium;
CVD: Cardiovascular disease; FDA: Food and drug Administration;
CPIC: Clinical Pharmacogenetics Implementation Consortium;
BBMRI: Biobanking and Biomolecular Resources Research Infrastructure.Competing interests
The authors declare that they have no competing interests.Authors’ contributions
AN, BM conceived and designed the experiments. KT contributed reagents/
materials/analysis tools. RS and BIM carried out Sanger sequencing analyses.
AG executed the PCR-RFLP genotyping. PM participated in the data analyses.
RS, CS and AN contributed to drafting the original version of the manuscript.
All authors have read and approved the manuscript.
Acknowledgement
This work was supported by the Hungarian National Science Foundation
grant (OTKA), the SROP-4.2.2/08/1/2008-0011 Science, Please! Research Team
on Innovation, the SROP-4.2.1.B-10/2/KONV-2010-0002, Developing the South
Transdanubian Regional University Competitiveness and the Janos Szenta-
gothai Research Centre.
Author details
11st Department of Internal Medicine, University of Pecs, Pecs, Hungary.
2Department of Medical Genetics, Clinical Centre, University of Pecs, Szigeti
12, H-7624 Pecs, Hungary. 3Janos Szentagothai Research Centre, Human
Genetic and Pharmacogenomic Research Group, University of Pecs, Pecs,
Hungary.
Received: 4 June 2015 Accepted: 12 August 2015
References
1. Kivisto KT, Niemi M. Influence of drug transporter polymorphisms on
pravastatin pharmacokinetics in humans. Pharm Res. 2007;24(2):239–47.
2. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting
polypeptide 1B1: a genetically polymorphic transporter of major importance
for hepatic drug uptake. Pharmacol Rev. 2011;63(1):157–81.
3. Gui C, Hagenbuch B. Amino acid residues in transmembrane domain 10 of
organic anion transporting polypeptide 1B3 are critical for cholecystokinin
octapeptide transport. Biochemistry. 2008;47(35):9090–7.
4. Niemi M. Role of OATP transporters in the disposition of drugs.
Pharmacogenomics. 2007;8(7):787–802.
5. Konig J, Cui Y, Nies AT, Keppler D. A novel human organic anion
transporting polypeptide localized to the basolateral hepatocyte membrane.
Am J Physiol Gastrointest Liver Physiol. 2000;278(1):G156–164.
6. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, et al. A novel human
hepatic organic anion transporting polypeptide (OATP2). Identification of a
liver-specific human organic anion transporting polypeptide and
identification of rat and human hydroxymethylglutaryl-CoA reductase
inhibitor transporters. J Biol Chem. 1999;274(52):37161–8.
7. Mangravite LM, Krauss RM. Pharmacogenomics of statin response. Curr Opin
Lipidol. 2007;18(4):409–14.
8. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights
into the pharmacodynamic and pharmacokinetic properties of statins.
Pharmacol Ther. 1999;84(3):413–28.
9. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al. SLCO1B1
variants and statin-induced myopathy–a genomewide study. N Engl J Med.
2008;359(8):789–99.
10. Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, et al. Genetic
polymorphisms of human organic anion transporters OATP-C (SLC21A6)
and OATP-B (SLC21A9): allele frequencies in the Japanese population and
functional analysis. J Pharmacol Exp Ther. 2002;302(2):804–13.
11. Oshiro C, Mangravite L, Klein T, Altman R. PharmGKB very important
pharmacogene: SLCO1B1. Pharmacogenet Genomics. 2010;20(3):211–6.
12. Francesca Notarangelo M, Marziliano N, Antonietta Demola M, Pigazzani F,
Guidorossi A, Angelica Merlini P, et al. Genetic predisposition to
atorvastatin-induced myopathy: a case report. J Clin Pharm Ther.
2012;37(5):604–6.
13. Danik JS, Chasman DI, MacFadyen JG, Nyberg F, Barratt BJ, Ridker PM. Lack
of association between SLCO1B1 polymorphisms and clinical myalgia
following rosuvastatin therapy. Am Heart J. 2013;165(6):1008–14.
14. Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, et al.
The clinical pharmacogenomics implementation consortium: CPIC guideline
for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther.
2012;92(1):112–7.
15. Irwin J, Egyed B, Saunier J, Szamosi G, O'Callaghan J, Padar Z, et al.
Hungarian mtDNA population databases from Budapest and the Baranya
county Roma. Int J Legal Med. 2007;121(5):377–83.
Nagy et al. BMC Genetics  (2015) 16:108 Page 7 of 716. Morar B, Gresham D, Angelicheva D, Tournev I, Gooding R, Guergueltcheva
V, et al. Mutation history of the roma/gypsies. Am J Hum Genet.
2004;75(4):596–609.
17. Kalaydjieva L, Gresham D, Calafell F. Genetic studies of the Roma (Gypsies):
a review. BMC Med Genet. 2001;2:5.
18. Kalaydjieva L, Calafell F, Jobling MA, Angelicheva D, de Knijff P, Rosser ZH,
et al. Patterns of inter- and intra-group genetic diversity in the Vlax Roma as
revealed by Y chromosome and mitochondrial DNA lineages. Eur J Hum
Genet. 2001;9(2):97–104.
19. Guglielmino CR, De Silvestri A, Beres J. Probable ancestors of Hungarian
ethnic groups: an admixture analysis. Ann Hum Genet. 2000;64(Pt 2):145–59.
20. Sipeky C, Lakner L, Szabo M, Takacs I, Tamasi V, Polgar N, et al. Interethnic
differences of CYP2C9 alleles in healthy Hungarian and Roma population
samples: relationship to worldwide allelic frequencies. Blood Cells Mol Dis.
2009;43(3):239–42.
21. Sipeky C, Csongei V, Jaromi L, Safrany E, Polgar N, Lakner L, et al. Vitamin K
epoxide reductase complex 1 (VKORC1) haplotypes in healthy Hungarian
and Roma population samples. Pharmacogenomics. 2009;10(6):1025–32.
22. Sipeky C, Csongei V, Jaromi L, Safrany E, Maasz A, Takacs I, et al. Genetic
variability and haplotype profile of MDR1 (ABCB1) in Roma and Hungarian
population samples with a review of the literature. Drug Metab
Pharmacokinet. 2011;26(2):206–15.
23. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics.
Br J Pharmacol. 2009;158(3):693–705.
24. Romaine SP, Bailey KM, Hall AS, Balmforth AJ. The influence of SLCO1B1
(OATP1B1) gene polymorphisms on response to statin therapy.
Pharmacogenomics J. 2010;10(1):1–11.
25. Alencastro de Azevedo L, Reverbel da Silveira T, Carvalho CG, Martins de
Castro S, Giugliani R, Matte U. UGT1A1, SLCO1B1, and SLCO1B3
polymorphisms vs. neonatal hyperbilirubinemia: is there an association?
Pediatr Res. 2012;72(2):169–73.
26. Santos PC, Gagliardi AC, Miname MH, Chacra AP, Santos RD, Krieger JE, et al.
SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia
in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharmacol.
2012;68(3):273–9.
27. Dendramis G. Interindividual differences in the response to statin therapy
and gene polymorphisms related to myopathy during statin therapy. G Ital
Cardiol (Rome). 2011;12(3):182–5.
28. Melo MS, Balanco L, Branco CC, Mota-Vieira L. Genetic variation in key
genes associated with statin therapy in the Azores Islands (Portugal) healthy
population. Ann Hum Biol. 2015;42(3):283–9.
29. Hubacek JA, Dlouha D, Adamkova V, Zlatohlavek L, Viklicky O, Hruba P, et al.
SLCO1B1 polymorphism is not associated with risk of statin-induced
myalgia/myopathy in a Czech population. Med Sci Monit. 2015;21:1454–9.
30. Li LM, Chen L, Deng GH, Tan WT, Dan YJ, Wang RQ, et al. SLCO1B1 *15
haplotype is associated with rifampin-induced liver injury. Mol Med Rep.
2012;6(1):75–82.
31. Hardy GH. Mendelian Proportions in a Mixed Population. Science.
1908;28(706):49–50.
32. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype
reconstruction from population data. Am J Hum Genet. 2001;68(4):978–89.
33. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype
reconstruction from population genotype data. Am J Hum Genet.
2003;73(5):1162–9.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
